| Literature DB >> 32024274 |
Magdalena Obieziurska1, Agata J Pacuła1, Anna Laskowska1, Angelika Długosz-Pokorska2, Anna Janecka2, Jacek Ścianowski1.
Abstract
Organoselenium compounds are well-known glutathione peroxidase (GPx) mimetics that possess antioxidants/prooxidant properties and are able to modulate the concentration of reactive oxygen species (ROS), preventing oxidative stress in normal cells or inducing ROS formation in cancer cells leading to apoptosis. The purpose of this study was the synthesis of potent GPx mimics with antioxidant and anticancer activity along with improved bioavailability, as a result of good solubility in protic solvents. As a result of our research, glutathione peroxidase (GPx) mimetics in the form of water-soluble benzeneseleninic acid salts were obtained. The procedure was based on the synthesis of 2-(N-alkylcarboxyamido)benzeneselenenic acids, through the oxidation of benzisoselenazol-3(2H)-ones or analogous arenediselenides with an amido group, which were further converted to corresponding potassium salts by the treatment with potassium tert-butanolate. All derivatives were tested as potential antioxidants and anticancer agents. The areneseleninic acid salts were significantly better peroxide scavengers than analogous acids and the well-known organoselenium antioxidant ebselen. The highest activity was observed for the 2-(N-ethylcarboxyamido)benzeneselenenic acid potassium salt. The strongest cytotoxic effect against breast cancer (MCF-7) and human promyelocytic leukemia (HL-60) cell lines was found for 2-(N-cyclohexylcarboxyamido)benzeneselenenic acid potassium salt and the 2-(N-ethylcarboxyamido)benzeneselenenic acid, respectively. The structure-activity correlations, including the differences in reactivity of benzeneseleninic acids and corresponding salts were evaluated.Entities:
Keywords: amphiphilic compounds; antioxidant activity; antiproliferative activity; areneseleninic acid salts; areneseleninic acids
Year: 2020 PMID: 32024274 PMCID: PMC7040810 DOI: 10.3390/ma13030661
Source DB: PubMed Journal: Materials (Basel) ISSN: 1996-1944 Impact factor: 3.623
Scheme 1GPx activity cycle at physiological conditions and elevated ROS levels.
Scheme 2Origin of the structure of the designed antioxidants 4 and 5.
Scheme 3Sythesis of benzeneseleninic acids 10–15 and corresponding potassium salts 16–21.
Figure 1Decomposition of benzeneseleninic acid 15 to the corresponding benzisoselenazolone.
Results of the antioxidant activity measurement.
| Catalyst (0.1 equiv.) | Remaining DTTred (%) | ||||
|---|---|---|---|---|---|
| 3 min | 5 min | 15 min | 30 min | 60 min | |
| Ebselen, 7 | 84 | 75 | 64 | 58 | 52 |
| Benzseleninic acids | |||||
| 10 | 89 | 86 | 78 | 67 | 51 |
| 11 | 81 | 75 | 70 | 63 | 51 |
| 12 | 85 | 82 | 75 | 65 | 47 |
| 13 | 89 | 85 | 69 | 46 | 19 |
| 14 | 76 | 56 | 38 | 24 | 12 |
| 15 | 85 | 64 | 37 | 18 | 2 |
| Benzseleninic acid salts 16–21 | 0 | 0 | 0 | 0 | 0 |
Results of the antioxidant activity measurement – 0.01 eq. of Se-catalyst.
| Catalyst | Remaining DTT (%) | t-Test | Mann-Whitney Test | ||||
|---|---|---|---|---|---|---|---|
| 3 min | 5 min | 15 min | 30 min | 60 min | p-value | p-value | |
| Ebselen, 7 | 97 | 96 | 95 | 94 | 92 | <0.001 | <0.015 |
| 16 | 24 | 11 | 0 | 0 | 0 | <0.005 | <0.015 |
| 17 | 76 | 45 | 21 | 14 | 11 | <0.005 | <0.015 |
| 18 | 71 | 63 | 26 | 17 | 14 | <0.01 | <0.015 |
| 19 | 81 | 63 | 17 | 0 | 0 | <0.001 | <0.015 |
| 20 | 59 | 16 | 0 | 0 | 0 | <0.005 | <0.015 |
| 21 | 78 | 18 | 3 | 0 | 0 | <0.001 | <0.015 |
Results of the antioxidant activity measurement performed in D2O – 0.0075 eq. of Se-catalyst.
| Catalyst. | 16 | 17 | 18 | 19 | 20 | 21 | PhSeOOK | No Catalyst |
|---|---|---|---|---|---|---|---|---|
|
| 19 | 47 | 15 | 46 | 79 | 26 | 49 | 93 |
Cytotoxic activity of acids 1–14 and corresponding salts 16–20.
| Structure | MCF-7 | HL-60 | Structure | MCF-7 | HL-60 |
|---|---|---|---|---|---|
|
| 40.1 ± 1.2 | 11.7 ± 1.0 |
| 31.5 ± 1.2 | 56.8 ± 4.4 |
|
| 71.9 ± 4.1 | 23.5 ± 1.1 |
| 20.6 ± 2.5 | 63.1 ± 0.5 |
|
| 42.5 ± 0.8 | 62.1 ± 8.0 |
| 101.4 ± 2.3 | 92.6 ± 4.7 |
|
| 65.4 ± 0.9 | 113 ± 9.1 |
| 45 ± 0.2 | 200 ± 14.3 |
|
| 40.8 ± 4.5 | 51.5 ± 4.5 |
| 26.5 ± 3.5 | 72.5 ± 4.3 |
|
| 45.9 ± 5.3 | 70.8 ± 1.3 |
| 16.6 ± 1.1 | 42.1 ± 3.1 |
| Carboplatin | 3.80 ± 0.45 | 2.9 ± 0.1 |